Real-World Safety and Effectiveness of Benralizumab in Japanese Patients with Severe Asthma: A Multicenter Prospective Observational Study

Overview

Journal J Asthma Allergy

Publisher Dove Medical Press

Date 2024 Jan 25

PMID 38268535

Authors

Masao Yamaguchi

Yoshihiro Nishimura

Yuko Takumi

Nobuya Hayashi

Kei Sakamoto

Yuji Tohda

Affiliations

Soon will be listed here.

Abstract

Introduction: This study aimed to demonstrate whether benralizumab maintained the safety and effectiveness profiles established in randomized controlled trials among all patients with severe uncontrolled asthma initially prescribed benralizumab in the real-world setting in Japan.

Methods: This was a prospective, observational, multicenter post-marketing study (ClinicalTrial.gov, NCT03588546). The safety and tolerability of benralizumab over 1 year were assessed by the incidence of adverse events (AEs), serious AEs, adverse drug reactions (ADRs), and serious ADRs. Patient background characteristics indicating a more frequent onset of ADRs with benralizumab were explored. The main effectiveness assessment was the change in Asthma Control Questionnaire-5 (ACQ-5) score from baseline. Patients with baseline ACQ-5 scores ≥1.5 were defined as having severe uncontrolled asthma.

Results: In total, 632 patients were evaluated for safety and 274 for effectiveness; 139 patients were included in the severe uncontrolled asthma subgroup. ADRs were reported in 12.7% and serious AEs in 13.0% of patients. Serious infections occurred in 3.8%, serious hypersensitivity in 0.3%, and malignancy in 0.3% of patients. No helminthic infections occurred. In the effectiveness population, benralizumab improved the mean (standard deviation [95% confidence interval]) ACQ-5 score by -1.16 (1.40 [-1.36, -0.96]) from baseline; forced expiratory volume in 1 second by 0.151 (0.440 [0.09, 0.21]) L; and Mini-Asthma Quality of Life questionnaire score by 1.16 (1.29 [0.94, 1.38]) at the last observation. The annual asthma exacerbation rate was 0.42. A greater ACQ-5 score improvement was observed among patients with eosinophilic asthma characteristics.

Conclusion: No new safety concerns were raised, and patients experienced benefits consistent with previous studies of benralizumab, thus supporting the use of benralizumab for the add-on maintenance treatment of patients with eosinophilic severe uncontrolled asthma.

Citing Articles

Benralizumab Outcomes in Patients with Severe Eosinophilic Asthma Treated in Real-Life Settings: Results of the BREEZE Study in 5 Countries From Central Eastern Europe and Baltics.

Mihaltan F, Csoma Z, Pauk N, Iras B, Baukiene J, Teodorescu G J Asthma Allergy. 2025; 18:195-210.

PMID: 39990056 PMC: 11844207. DOI: 10.2147/JAA.S503048.

Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions.

Jappe U, Bergmann K, Brinkmann F, Faihs V, Gulsen A, Klimek L Allergol Select. 2024; 8:365-406.

PMID: 39600395 PMC: 11590746. DOI: 10.5414/ALX02533E.

References

Nair P, Wenzel S, Rabe K, Bourdin A, Lugogo N, Kuna P . Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017; 376(25):2448-2458. DOI: 10.1056/NEJMoa1703501. View

Kavanagh J, Hearn A, Dhariwal J, dAncona G, Douiri A, Roxas C . Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. Chest. 2020; 159(2):496-506. DOI: 10.1016/j.chest.2020.08.2083. View

Numata T, Araya J, Okuda K, Miyagawa H, Minagawa S, Ishikawa T . Long-Term Efficacy and Clinical Remission After Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study. J Asthma Allergy. 2022; 15:1731-1741. PMC: 9719274. DOI: 10.2147/JAA.S391807. View

Tan Y, Papez V, Chang W, Mueller S, Denaxas S, Lai A . Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England. Lancet Healthy Longev. 2022; 3(10):e674-e689. DOI: 10.1016/S2666-7568(22)00186-6. View

Busse W, Bleecker E, FitzGerald J, Ferguson G, Barker P, Sproule S . Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2018; 7(1):46-59. DOI: 10.1016/S2213-2600(18)30406-5. View

Adachi M, Kozawa M, Yoshisue H, Milligan K, Nagasaki M, Sasajima T . Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan. Respir Med. 2018; 141:56-63. DOI: 10.1016/j.rmed.2018.06.021. View

Senna G, Aliani M, Altieri E, Bracciale P, Brussino L, Caiaffa M . Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm: A Post Hoc Analysis from the ANANKE Study. J Asthma Allergy. 2022; 15:1593-1604. PMC: 9661992. DOI: 10.2147/JAA.S383012. View

Bleecker E, FitzGerald J, Chanez P, Papi A, Weinstein S, Barker P . Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 388(10056):2115-2127. DOI: 10.1016/S0140-6736(16)31324-1. View

Nagase H, Adachi M, Matsunaga K, Yoshida A, Okoba T, Hayashi N . Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int. 2019; 69(1):53-60. DOI: 10.1016/j.alit.2019.06.003. View

10.

Poddighe D, Kovzel E . Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome. J Inflamm Res. 2021; 14:6845-6853. PMC: 8684423. DOI: 10.2147/JIR.S345665. View

11.

Wang E, Wechsler M, Tran T, Heaney L, Jones R, Menzies-Gow A . Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry. Chest. 2019; 157(4):790-804. DOI: 10.1016/j.chest.2019.10.053. View

12.

Pilette C, Canonica G, Chaudhuri R, Chupp G, Lee F, Lee J . REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma. J Allergy Clin Immunol Pract. 2022; 10(10):2646-2656. DOI: 10.1016/j.jaip.2022.05.042. View

13.

Menzies-Gow A, McBrien C, Unni B, Porsbjerg C, Al-Ahmad M, Ambrose C . Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study. J Asthma Allergy. 2022; 15:63-78. PMC: 8763264. DOI: 10.2147/JAA.S328653. View

14.

Inoue H, Kozawa M, Milligan K, Funakubo M, Igarashi A, Loefroth E . A retrospective cohort study evaluating healthcare resource utilization in patients with asthma in Japan. NPJ Prim Care Respir Med. 2019; 29(1):13. PMC: 6488614. DOI: 10.1038/s41533-019-0128-8. View

15.

Eger K, Kroes J, Ten Brinke A, Bel E . Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation. J Allergy Clin Immunol Pract. 2020; 9(3):1194-1200. DOI: 10.1016/j.jaip.2020.10.010. View

16.

Nakamura Y, Tamaoki J, Nagase H, Yamaguchi M, Horiguchi T, Hozawa S . Japanese guidelines for adult asthma 2020. Allergol Int. 2020; 69(4):519-548. DOI: 10.1016/j.alit.2020.08.001. View

17.

Thelen J, van Zelst C, van Brummelen S, Rauh S, In t Veen J, Kappen J . Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: A real-world Dutch cohort study. Respir Med. 2022; 206:107058. DOI: 10.1016/j.rmed.2022.107058. View

18.

Inghammar M, Engstrom G, Kahlmeter G, Ljungberg B, Lofdahl C, Egesten A . Invasive pneumococcal disease in patients with an underlying pulmonary disorder. Clin Microbiol Infect. 2013; 19(12):1148-54. DOI: 10.1111/1469-0691.12182. View

19.

Belda J, Parameswaran K, Lemiere C, Kamada D, OByrne P, Hargreave F . Predictors of loss of asthma control induced by corticosteroid withdrawal. Can Respir J. 2006; 13(3):129-33. PMC: 2539017. DOI: 10.1155/2006/189127. View

20.

Kolbeck R, Kozhich A, Koike M, Peng L, Andersson C, Damschroder M . MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010; 125(6):1344-1353.e2. DOI: 10.1016/j.jaci.2010.04.004. View